Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

2(14%)

Results Posted

17%(1 trials)

Terminated

1(7%)

Phase Distribution

Ph phase_3

43%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 2Efficacy & side effects

7(53.8%)

Phase 3Large-scale testing

6(46.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(6)

Terminated(2)

Other(3)

Detailed Status

Completed6

unknown3

Recruiting2

Withdrawn1

Not yet recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 3

Trials by Phase

Phase 27 (53.8%)

Phase 36 (46.2%)

Trials by Status

completed643%

unknown321%

withdrawn17%

recruiting214%

not_yet_recruiting17%

terminated17%

Recent Activity

2 active trials

Showing 5 of 14

recruitingphase_3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

NCT06346197

completedphase_2

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

NCT05039944

View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials

NCT06346197Phase 3

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Recruiting

NCT03259035Phase 2

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

Completed

NCT02967289Phase 3

IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

Completed

NCT04516681Phase 3

Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer

Recruiting

NCT05039944Phase 2

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Terminated

NCT04962958Phase 2

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Unknown

NCT02973685Phase 3

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

Completed

NCT05494320

the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin

Unknown

NCT02774187Phase 3

Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

Completed

NCT03975049Phase 3

Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Not Yet Recruiting

NCT03803254Phase 2

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Withdrawn

NCT02981498Phase 2

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

Completed

NCT03812783Phase 2

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Unknown

NCT03048123Phase 2

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

Completed

All 14 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 14